Efetividade e segurança da terapia tripla com boceprevir ou telaprevir no tratamento da hepatite C crônica genótipo 1 em pacientes atendidos em centros de referência no Brasil

Efetividade e segurança da terapia tripla com boceprevir ou telaprevir no tratamento da hepatite C crônica genótipo 1 em pacientes atendidos em centros de referência no Brasil

INTRODUÇÃO: No Brasil, no período compreendido entre 2013 a 2015, a terapia tripla com boceprevir (BOC) ou telaprevir (TVR) foi o tratamento padrão para pacientes infectados pelo vírus da hepatite C (VHC) genótipo 1. OBJETIVOS: Avaliar a efetividade e a segurança da terapia tripla com BOC ou TVR...

Full description

Bibliographic Details
Main Author:	Luciana Azevêdo Callefi
Other Authors:	Maria Cassia Jacintho Mendes Corrêa
Language:	Portuguese
Published:	Universidade de São Paulo 2017
Subjects:	Boceprevir Efetividade Estudo de vida real Hepatite C crônica Inibidores de protease Segurança Telaprevir Terapêutica Effectiveness Hepatitis C chronic Protease inhibitors Real life study Safety Therapeutics
Online Access:	http://www.teses.usp.br/teses/disponiveis/5/5134/tde-04082017-100925/

Similar Items

Efetividade e segurança da terapia tripla com boceprevir ou telaprevir no tratamento da hepatite C crônica genótipo 1 em pacientes atendidos em centros de referência no Brasil
by: Callefi, Luciana Azevêdo
Published: (2017)

Boceprevir and telaprevir utilization evaluation for the treatment of chronic hepatitis C
by: P. Marrero-Álvarez, et al.
Published: (2014-01-01)

Telaprevir or Boceprevir for Hepatitis C treatment: a first survey of pharmacoutilization
by: Maurizio eCapuozzo, et al.
Published: (2013-09-01)

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
by: Borba HHL, et al.
Published: (2017-01-01)

The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
by: Midori Kjellin, et al.
Published: (2018-01-01)

Avaliação do tratamento de hepatite C crônica, no ambulatório do Conjunto Hospitalar de Sorocaba, com o uso do Telaprevir e sua relação com as desordens tireoidianas
by: Fernando José Goés Ruiz, et al.
Published: (2016-10-01)

Triple therapy for chronic hepatitis C: Practical Aspects
by: I G Bakulin, et al.
Published: (2013-11-01)

Efetividade e segurança dos inibidores da protease de primeira geração indicados ao tratamento de pacientes cronicamente infectados pelo genótipo 1 do HCV
by: Rodrigues, João Paulo Vilela
Published: (2017)

Efetividade e segurança dos inibidores da protease de primeira geração indicados ao tratamento de pacientes cronicamente infectados pelo genótipo 1 do HCV
by: Rodrigues, João Paulo Vilela
Published: (2017)

Efetividade e segurança dos inibidores da protease de primeira geração indicados ao tratamento de pacientes cronicamente infectados pelo genótipo 1 do HCV
by: Rodrigues, João Paulo Vilela
Published: (2017)

Treatment of hepatitis C virus infection in the future
by: Tatsuo Kanda, et al.
Published: (2013-12-01)

http://www.aulamedica.es/fh/pdf/1129.pdf
by: R. López-Sepúlveda, et al.
Published: (2014-01-01)

First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients
by: Silvana Gama Florencio Chachá, et al.

Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry
by: Emma Gray, et al.
Published: (2017-04-01)

Avaliação da terapia tripla para tratamento da Hepatite C crônica utilizando Boceprevir e Telaprevir
by: Carneiro, Jane Meire Magalhães
Published: (2018)

An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver
by: Norberto C. Chávez-Tapia, et al.
Published: (2013-03-01)

Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia
by: Simonović-Babić Jasmina, et al.
Published: (2015-01-01)

Custo-efetividade da Terapia Tripla para pacientes adultos portadores do genótipo 1 da hepatite C crônica.
by: Renata Luzes Araújo
Published: (2015)

Custo-efetividade da Terapia Tripla para pacientes adultos portadores do genótipo 1 da hepatite C crônica.
by: Renata Luzes Araújo
Published: (2015)

On the cusp of change: New therapeutic modalities for HCV
by: Maribel Rodríguez-Torres
Published: (2010-01-01)

Boceprevir: New possibilities for the antiviral treatment of chronic hepatitis C
by: I G Nikitin, et al.
Published: (2013-02-01)

Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil
by: Cirley Maria de Oliveira Lobato, et al.

Significance of allelic variants of interleukin-28B gene in chronic hepatitis C
by: N Iu Tikhonova, et al.
Published: (2013-12-01)

Introduction and utilisation of high priced HCV medicines across Europe; implications for the future
by: Winnie de Bruijn, et al.
Published: (2016-07-01)

Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience
by: Nabiha Faisal, MD, FCPS, et al.
Published: (2014-09-01)

Betaleukin in therapy of chronic hepatitis C
by: E. S. Romanova, et al.
Published: (2014-10-01)

Análise da segurança e efetividade do tratamento da hepatite C crônica com inibidores de protease Telaprevir e Boceprevir em um centro de referência
by: Teixeira, Marina Rodrigues
Published: (2017)

Cutaneous Eruption due to Telaprevir
by: Eduardo Mastrangelo Marinho Falcão, et al.
Published: (2015-09-01)

Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese
by: Choi Y, et al.
Published: (2018-04-01)

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C
by: Xavier Forns, et al.
Published: (2016-07-01)

Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey
by: Orhan Yıldız, et al.
Published: (2015-09-01)

Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies
by: Amal Mahmoud, et al.
Published: (2021-09-01)

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance
by: Bruno Roche, et al.
Published: (2015-09-01)

Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin
by: Alejandro Soza, M.D., et al.
Published: (2015-01-01)

Telaprevir: New possibilities for antiviral treatment in patients with chronic hepatitis C
by: I G Nikitin, et al.
Published: (2012-11-01)

Telaprevir: Changing the standard of care of chronic hepatitis C
by: A K Rajani, et al.
Published: (2013-01-01)

Comparative analysis of the safety of triple therapy with telaprevir between HCV monoinfected and HIV coinfected patients
by: C. Sangrador Pelluz, et al.
Published: (2014-01-01)

The use of telaprevir for the treatment of hepatitis C in patients undergoing liver transplantation (Literature review and clinical experience)
by: M. Sh. Khubutiya, et al.
Published: (2016-02-01)

First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder
by: Nawal Al Nahdi, et al.
Published: (2013-01-01)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
by: Lenyta Oliveira Gomes, et al.
Published: (2018-06-01)

Cannot write session to /tmp/vufind_sessions/sess_j48mbeonr5bce9mistubjr9gbf